AI-generated from publicly available materials.Lantern Pharma has reported a significant reduction in the costs associated with advancing oncology programs to first-in-human clinical trials, utilizing its AI-driven drug development model. The company claims that this approach allows for development costs to be as low as $2 million to $3 million per program, a stark contrast to the industry standard of $25 million to $100 million.
The company's RADR platform leverages artificial intelligence and machine learning to expedite the drug development process, typically moving from initial insights to clinical trials within two to three years, compared to the conventional timeline of five to ten years. This efficiency not only streamlines the development process but also targets a substantial market opportunity exceeding $15 billion annually.
In addition to its oncology initiatives, Lantern has established Open Medicine AI (OMAI) as a separate entity to further monetize its AI technology. OMAI will operate as a commercial software business, offering tiered subscriptions and enterprise agreements to various stakeholders in the life sciences sector. Lantern plans to retain a significant ownership stake while seeking external investment to facilitate OMAI's growth and potential future public listing.
As Lantern continues to utilize its AI platform in ongoing trials, such as the Phase 2 HARMONIC trial for LP-300, early data shows promising results, including an improvement in progression-free survival rates among specific patient populations. This dual focus on cost-effective drug development and innovative AI applications positions Lantern Pharma as a notable player in the evolving landscape of life sciences.